Lifeward Ltd. Reports 14% Revenue Decline for Fiscal Year 2025

**Lifeward Ltd. Reports Fiscal Year 2025 Results, Revenue Declines by 14%**

Lifeward Ltd., formerly ReWalk Robotics Ltd., an Israeli-based medical device company, reported its financial results for the fiscal year ended December 31, 2025. The company's revenue totaled $22.03 million, a decrease of 14% compared to the $25.66 million reported in 2024. This decline was primarily attributed to a $3.0 million decrease in AlterG sales, due to lower international demand and fewer system shipments, and a $0.6 million decrease in revenue from MyoCycle. The company's gross profit increased slightly to $8.43 million, representing 38% of revenue, compared to $8.22 million, or 32% of revenue, in the previous year. The increase in gross margin was primarily attributable to the absence in 2025 of approximately $1.5 million of amortization expenses and $1.2 million of restructuring expenses recognized in 2024.

Operating expenses decreased by 25% to $28.10 million in 2025, compared to $37.56 million in 2024. Research and development expenses decreased by 30% to $3.25 million, primarily due to the completion of development projects for the ReWalk 7 and NEO products. Sales and marketing expenses decreased by 23% to $13.88 million, driven by lower reimbursement, trade show, and marketing consultant expenses, as well as reductions in headcount, sales commissions, and travel-related costs. General and administrative expenses increased by 58% to $8.20 million, primarily due to restructuring expenses and transaction-related costs incurred in connection with the Oramed transaction. The company recorded a goodwill impairment charge of $2.78 million in 2025, compared to $9.79 million in 2024.

Lifeward reported a net loss of $19.91 million for 2025, compared to a net loss of $28.94 million in 2024. The company's net loss per ordinary share, basic and diluted, was $17.16, compared to $39.96 in the previous year. As of December 31, 2025, Lifeward had cash and cash equivalents of $2.17 million. The company has concluded that substantial doubt exists about its ability to continue as a going concern.

In January 2026, Lifeward entered into a Share Purchase Agreement with Oramed Pharmaceuticals, Inc. and Oratech Pharma, Inc., to acquire all of the outstanding equity interests of Oratech. In connection with the transaction, Lifeward also entered into a Securities Purchase Agreement with Oramed and certain investors providing for the issuance of up to $20.0 million of senior secured convertible notes. In February 2026, Lifeward effected a 1-for-12 reverse share split of its ordinary shares. The company anticipates closing the transaction following the satisfaction of customary closing conditions.